Free Trial

Vertex Pharmaceuticals (VRTX) Competitors

Vertex Pharmaceuticals logo
$447.18 +6.52 (+1.48%)
As of 05/20/2025 04:00 PM Eastern

VRTX vs. AMGN, GILD, REGN, ALNY, BIIB, UTHR, NBIX, BMRN, INCY, and EXEL

Should you be buying Vertex Pharmaceuticals stock or one of its competitors? The main competitors of Vertex Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), Incyte (INCY), and Exelixis (EXEL). These companies are all part of the "biotechnology" industry.

Vertex Pharmaceuticals vs.

Amgen (NASDAQ:AMGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, community ranking, risk, analyst recommendations and media sentiment.

76.5% of Amgen shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 0.8% of Amgen shares are owned by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Vertex Pharmaceuticals received 49 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 74.83% of users gave Vertex Pharmaceuticals an outperform vote while only 71.71% of users gave Amgen an outperform vote.

CompanyUnderperformOutperform
AmgenOutperform Votes
1559
71.71%
Underperform Votes
615
28.29%
Vertex PharmaceuticalsOutperform Votes
1608
74.83%
Underperform Votes
541
25.17%

Amgen has higher revenue and earnings than Vertex Pharmaceuticals. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$34.13B4.33$4.09B$10.9625.09
Vertex Pharmaceuticals$11.10B10.35-$535.60M-$3.92-114.08

Amgen has a net margin of 12.24% compared to Vertex Pharmaceuticals' net margin of -4.86%. Amgen's return on equity of 176.32% beat Vertex Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Amgen12.24% 176.32% 11.71%
Vertex Pharmaceuticals -4.86%-2.02%-1.49%

In the previous week, Amgen had 10 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 38 mentions for Amgen and 28 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.48 beat Amgen's score of 1.27 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amgen
24 Very Positive mention(s)
5 Positive mention(s)
4 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive
Vertex Pharmaceuticals
23 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Amgen currently has a consensus target price of $309.22, indicating a potential upside of 12.44%. Vertex Pharmaceuticals has a consensus target price of $515.04, indicating a potential upside of 15.18%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Amgen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amgen
2 Sell rating(s)
12 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.38
Vertex Pharmaceuticals
0 Sell rating(s)
13 Hold rating(s)
15 Buy rating(s)
1 Strong Buy rating(s)
2.59

Amgen has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500.

Summary

Amgen beats Vertex Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Vertex Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRTX vs. The Competition

MetricVertex PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$114.83B$6.55B$5.43B$8.47B
Dividend YieldN/A2.66%5.22%4.11%
P/E Ratio-203.269.1426.8320.05
Price / Sales10.35257.54394.48119.51
Price / CashN/A65.8538.2534.62
Price / Book7.006.546.874.61
Net Income-$535.60M$143.51M$3.22B$248.10M
7 Day Performance3.51%4.66%5.65%2.88%
1 Month Performance-8.57%10.63%13.54%15.41%
1 Year Performance0.29%-1.05%18.16%7.68%

Vertex Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRTX
Vertex Pharmaceuticals
4.6606 of 5 stars
$447.18
+1.5%
$515.04
+15.2%
+0.3%$114.83B$11.10B-203.264,800Positive News
AMGN
Amgen
4.622 of 5 stars
$275.03
+3.4%
$310.23
+12.8%
-12.6%$148.11B$34.13B36.4825,200Positive News
Analyst Upgrade
GILD
Gilead Sciences
4.6931 of 5 stars
$104.01
+7.3%
$110.55
+6.3%
+60.7%$129.57B$28.74B281.2417,000Positive News
Options Volume
REGN
Regeneron Pharmaceuticals
4.8231 of 5 stars
$576.35
+9.2%
$892.60
+54.9%
-37.7%$63.03B$14.09B15.0611,900Trending News
Dividend Announcement
Gap Up
ALNY
Alnylam Pharmaceuticals
3.7096 of 5 stars
$266.32
+6.0%
$319.17
+19.8%
+94.1%$34.83B$2.35B-123.112,000Positive News
BIIB
Biogen
4.9168 of 5 stars
$124.12
+5.0%
$191.30
+54.1%
-43.6%$18.21B$9.82B11.118,720Analyst Revision
UTHR
United Therapeutics
4.9819 of 5 stars
$311.40
+3.3%
$392.00
+25.9%
+12.7%$14.05B$2.99B13.68980
NBIX
Neurocrine Biosciences
4.9305 of 5 stars
$120.12
+3.8%
$162.00
+34.9%
-13.2%$11.87B$2.41B36.451,200Positive News
BMRN
BioMarin Pharmaceutical
4.9841 of 5 stars
$61.67
+4.8%
$93.45
+51.5%
-22.2%$11.83B$2.95B28.053,080Positive News
Insider Trade
Gap Up
INCY
Incyte
4.8942 of 5 stars
$60.93
+3.3%
$73.53
+20.7%
+14.2%$11.79B$4.41B225.512,320Positive News
EXEL
Exelixis
4.0655 of 5 stars
$37.09
+2.6%
$37.59
+1.3%
+110.6%$10.25B$2.17B21.011,220Positive News

Related Companies and Tools


This page (NASDAQ:VRTX) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners